Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Other Operating Expenses: 2023

Historic Other Operating Expenses for Spyre Therapeutics (SYRE) over the last 1 years, with Dec 2023 value amounting to $16.4 million.

  • Spyre Therapeutics' Other Operating Expenses was N/A to -$10.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $136.9 million, marking a year-over-year change of. This contributed to the annual value of $16.4 million for FY2023, which is N/A change from last year.
  • Per Spyre Therapeutics' latest filing, its Other Operating Expenses stood at $16.4 million for FY2023.
  • Spyre Therapeutics' Other Operating Expenses' 5-year high stood at $16.4 million during FY2023, with a 5-year trough of $16.4 million in FY2023.
  • Over the past 1 years, Spyre Therapeutics' median Other Operating Expenses value was $16.4 million (recorded in 2023), while the average stood at $16.4 million.